Andrew Blauvelt

Blauvelt Consulting, LLC, Annapolis, MD, USA

Poster(s):

• (A-048) Dupilumab Demonstrates a Higher Benefit-risk Score Compared with Upadacitinib: A Structured Benefit-risk Assessment of the HEADS UP Trial
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET